ArticleMolecules (Basel, Switzerland)2019
Chlojaponilactone B Attenuates Lipopolysaccharide-Induced Inflammatory Responses by Suppressing TLR4-Mediated ROS Generation and NF-κB Signaling Pathway.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Immunomodulatory effects of TAK-242 on osteogenesis of mesenchymal stem cells in acute inflammatory conditions.BMC molecular and cell biology · 2026Article
- Studies of chitosan-Prussian blue nanozyme in auditory protection: from cellular mechanisms toFrontiers in immunology · 2026Article
- A multi-mics exploration of programmed cell death in non-obstructive azoospermia: identifying TLR4 as a central regulator and therapeutic target.Frontiers in cell and developmental biology · 2026Article
- Article
- STAT3 blockade ameliorates LPS-induced kidney injury through macrophage-driven inflammation.Cell communication and signaling : CCS · 2024Article
- Binding affinity screening of polyphenolic compounds in Stachys affinis extract (SAE) for their potential antioxidant and anti-inflammatory effects.Scientific reports · 2024Article
- Article
- Chlojaponilactone B Attenuates THP-1 Macrophage Pyroptosis by Inhibiting the TLR/MyD88/NF-κB Pathway.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Potential Antioxidant and Anti-Inflammatory Properties of Polyphenolic Compounds fromInternational journal of molecular sciences · 2024Article
- The role of oxidative stress in aortic dissection: a potential therapeutic target.Frontiers in cardiovascular medicine · 2024Review
- Role of Pyroptosis, a Pro-inflammatory Programmed Cell Death, in Epilepsy.Cellular and molecular neurobiology · 2023Review
- Article
- Neuroprotective Effects of a New Derivative of Chlojaponilactone B against Oxidative Damaged Induced by Hydrogen Peroxide in PC12 Cells.Molecules (Basel, Switzerland) · 2022Article
- Antimicrobial peptide CC34 attenuates intestinal inflammation via downregulation of the NF-κB signaling pathway.3 Biotech · 2021Article
- Editorial to Special Issue-Anti-Inflammatory Activity of Natural Products.Molecules (Basel, Switzerland) · 2020Article
- Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The lindenane-type sesquiterpenoid chlojaponilactone B (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.